Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health has incorporated its subsidiary, Napo EU, in Italy to combat inflammatory diarrhea linked to long-hauler syndrome post-COVID-19, primarily in Europe. The subsidiary is the target of a forthcoming merger with the Dragon SPAC, expected to list on AIM Italia. CEO Lisa Conte announced the search for key management roles and ongoing regulatory efforts to gain conditional marketing authorization from the European Medicines Agency (EMA).

Jaguar Health has signed a definitive agreement for a $5 million non-dilutive royalty financing transaction, related to future sales of crofelemer (Mytesi) for a COVID-related indication targeting long-hauler patients. This financing will support regulatory activities and the development pipeline for crofelemer. The company is also identifying key opinion leaders in the US and Europe to address symptoms affecting COVID-19 survivors. With no royalty payments due for 36 months, Jaguar aims to leverage this opportunity to explore the growing market of long-hauler syndrome.

Jaguar Health has signed a binding agreement for a $5 million non-dilutive royalty financing to support the development of crofelemer for a COVID-related indication in long-hauler patients. This financing adds to previous transactions totaling $12 million since late 2020. The company aims for accelerated conditional approval of crofelemer in the EU. The Dragon SPAC, targeting AIM Italia, will focus on Napo EU's projects, providing additional updates expected next week. Mytesi, approved by the FDA, serves as an anti-diarrheal for adults with HIV/AIDS.

Jaguar Health has launched the Napo EU website in Italy, providing resources on post-COVID-19 long-hauler syndrome, including gastrointestinal symptoms like diarrhea. The site links to relevant studies and aims to explore the conditional marketing authorization of crofelemer for inflammatory diarrhea in long-hauler patients in Europe. In a recent study, 30% of COVID-19 survivors reported ongoing symptoms, highlighting the potential market for Jaguar's Mytesi product. The company continues to advocate for its plant-based therapies targeting GI distress.

Jaguar Health (NASDAQ:JAGX) is advancing plans for an exclusive relationship with the Dragon SPAC, targeting the listing of its subsidiary, Napo EU, on AIM Italia. An MOU has been signed with Josh Mailman, the lead sponsor of Dragon SPAC, which will negotiate the merger with Napo EU. The company is also seeking conditional marketing authorization in Europe for crofelemer to treat inflammatory diarrhea, particularly among 'long-hauler' COVID-19 patients. A meeting with European regulatory authorities is scheduled for March 2021.

Jaguar Health (NASDAQ:JAGX) announced a Memorandum of Understanding (MOU) with the Dragon SPAC to enable Napo EU’s anticipated listing on AIM Italia. The focus is on seeking conditional marketing authorization for crofelemer to treat inflammatory diarrhea in long-hauler COVID-19 patients in Europe. The partnership aims to leverage Napo's experience in developing plant-based drugs, particularly crofelemer, which is currently used for noninfectious diarrhea in HIV/AIDS patients. The potential market includes 20-70 million people in Europe suffering from gastrointestinal issues related to long COVID.

Jaguar Health, Inc. (NASDAQ:JAGX) announced a webcast on January 27, 2021, at 8:30 AM ET to discuss updates on the proposed merger of its anticipated subsidiary Napo EU with a special purpose acquisition company (SPAC) focused on Post Pandemic Recovery. Jaguar is exploring conditional marketing authorization in Europe for crofelemer, aimed at addressing gastrointestinal issues in long-hauler COVID-19 patients. The webcast will feature CEO Lisa Conte and Andreea Porcelli as co-presenters.

Jaguar Health, Inc. (NASDAQ:JAGX) announced the granting of nonstatutory stock options to new employees as inducement awards. Effective December 9, 2020, one employee received options for 1,500 shares, while another received options for 35,000 shares, with an exercise price of $0.353. Additionally, on January 7, 2021, another employee was granted options for 7,000 shares at $2.68 per share. All options vest over three years, subject to continued employment. These options are part of the Company's strategy to attract and retain talent.

Jaguar Health, Inc. (NASDAQ:JAGX) announced on January 21, 2021, that it has regained compliance with Nasdaq's bid price requirement, as stated by the Nasdaq Hearings Panel on October 28, 2020. CEO Lisa Conte expressed satisfaction with this achievement, attributing it to the company's efforts since Q2 2020, such as expanding patient access to Mytesi^® and securing a $6 million royalty-based capital infusion. The company is also advancing a Phase 3 clinical trial for crofelemer aimed at treating cancer therapy-related diarrhea.